Overview of growth differentiation factor 15 (GDF15) in metabolic diseases
- PMID: 38810400
- DOI: 10.1016/j.biopha.2024.116809
Overview of growth differentiation factor 15 (GDF15) in metabolic diseases
Abstract
GDF15 is a stress response cytokine and a distant member of the transforming growth factor beta (TGFβ) superfamily, its levels increase in response to cell stress and certain diseases in the serum. To exert its effects, GDF15 binds to glial-derived neurotrophic factor (GDNF) receptor alpha-like (GFRAL), which was firstly identified in 2017 and highly expressed in the brain stem. Many studies have demonstrated that elevated serum GDF15 is associated with anorexia and weight loss. Herein, we focus on the biology of GDF15, specifically how this circulating protein regulates appetite and metabolism in influencing energy homeostasis through its actions on hindbrain neurons to shed light on its impact on diseases such as obesity and anorexia/cachexia syndromes. It works as an endocrine factor and transmits metabolic signals leading to weight reduction effects by directly reducing appetite and indirectly affecting food intake through complex mechanisms, which could be a promising target for the treatment of energy-intake disorders.
Keywords: Anorexia; Appetite regulation; GDF15; GFRAL; Metabolism; Obesity.
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.Cell Metab. 2018 Sep 4;28(3):353-368. doi: 10.1016/j.cmet.2018.07.018. Cell Metab. 2018. PMID: 30184485 Review.
-
The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?Annu Rev Physiol. 2021 Feb 10;83:127-151. doi: 10.1146/annurev-physiol-022020-045449. Epub 2020 Nov 23. Annu Rev Physiol. 2021. PMID: 33228454 Review.
-
Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.Trends Endocrinol Metab. 2018 Aug;29(8):560-570. doi: 10.1016/j.tem.2018.05.002. Epub 2018 Jun 1. Trends Endocrinol Metab. 2018. PMID: 29866502 Review.
-
GDF15 mediates adiposity resistance through actions on GFRAL neurons in the hindbrain AP/NTS.Int J Obes (Lond). 2019 Dec;43(12):2370-2380. doi: 10.1038/s41366-019-0365-5. Epub 2019 May 31. Int J Obes (Lond). 2019. PMID: 31152154
-
Targeting Obesity and Cachexia: Identification of the GFRAL Receptor-MIC-1/GDF15 Pathway.Trends Mol Med. 2017 Dec;23(12):1065-1067. doi: 10.1016/j.molmed.2017.10.005. Epub 2017 Nov 9. Trends Mol Med. 2017. PMID: 29129392
Cited by
-
Health implications of racial differences in serum growth differentiation factor levels among men with obesity.Physiol Rep. 2024 Dec;12(23):e70124. doi: 10.14814/phy2.70124. Physiol Rep. 2024. PMID: 39668628 Free PMC article.
-
GDF15 and its receptors as pathways mediating smoking related weight change.EBioMedicine. 2025 Jul;117:105806. doi: 10.1016/j.ebiom.2025.105806. Epub 2025 Jun 16. EBioMedicine. 2025. PMID: 40527012 Free PMC article.
-
Biomarkers for intensive care unit-acquired weakness: a systematic review for prediction, diagnosis and prognosis.Ann Intensive Care. 2025 Jul 2;15(1):86. doi: 10.1186/s13613-025-01500-9. Ann Intensive Care. 2025. PMID: 40601169 Free PMC article. Review.
-
Relevance of GDF15 as a biomarker for clinical outcomes after bariatric surgery.J Endocrinol. 2025 Jul 1;266(1):e250010. doi: 10.1530/JOE-25-0010. Print 2025 Jul 1. J Endocrinol. 2025. PMID: 40530451 Free PMC article.
-
Mechanisms and pharmacotherapy of cancer cachexia-associated anorexia.Pharmacol Res Perspect. 2025 Feb;13(1):e70031. doi: 10.1002/prp2.70031. Pharmacol Res Perspect. 2025. PMID: 39776294 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical